A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
Seattle-based Icosavax’s stock plunged more than 60 percent on March 25 after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
Pfizer announced March 24 that the company received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the vaccine candidate PF-06928316 (RSVpreF), intended to prevent infections caused by a respiratory syncytial virus (RSV).
Moderna reported positive interim results from the Phase II/III KidCOVE trial of the company’s mRNA COVID-19 vaccine for children six months to under two years and also two to six years of age.
Specialty vaccine company Valneva, along with Pfizer, reported positive Phase II data from their clinical trial evaluating a Lyme disease vaccine candidate.
BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
The U.S. Food and Drug Administration added another warning to the regulatory agency’s fact sheet for Johnson & Johnson’s COVID-19 vaccine. In other news, as the Omicron variant rips through the United States, top health officials have noted that the variant is so contagious that if you come into contact with it, you are likely to catch it.
French specialty vaccine company Valneva and U.S. drugmaker Pfizer reported positive results from the companies’ Phase II study on a vaccine candidate for Lyme disease.
Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.
French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.
